- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Call
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Shabih Shakeel
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Mark Eaton
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marco Herold
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sant-Rayn Pasricha
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A new regulator of 'stemness' to create dendritic cell factories for immunotherapy
- Advanced imaging interrogation of pathogen induced NETosis
- Cancer driver deserts
- Cryo-electron microscopy of Wnt signalling complexes
- Deciphering the heterogeneity of breast cancer at the epigenetic and genetic levels
- Developing drugs to block malaria transmission
- Developing new computational tools for CRISPR genomics to advance cancer research
- Developing novel antibody-based methods for regulating apoptotic cell death
- Discovering novel paradigms to cure viral and bacterial infections
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Do membrane forces govern assembly of the deadly apoptotic pore?
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- E3 ubiquitin ligases in neurodegeneration, autoinflammation and cancer
- Engineering improved CAR-T cell therapies
- Epigenetic biomarkers of tuberculosis infection
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- Genomic rearrangement detection with third generation sequencing technology
- How does DNA damage shape disease susceptibility over a lifetime?
- How does DNA hypermutation shape the development of solid tumours?
- How platelets prevent neonatal stroke
- Human lung protective immunity to tuberculosis
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of dysregulated Tom40 in neurodegeneration
- Investigating the role of mutant p53 in cancer
- Lupus: proteasome inhibitors and inflammation
- Machine learning methods for somatic genome rearrangement detection
- Malaria: going bananas for sex
- Measurements of malaria parasite and erythrocyte membrane interactions using cutting-edge microscopy
- Measuring susceptibility of cancer cells to BH3-mimetics
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Mutational signatures of structural variation
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Revealing the epigenetic origins of immune disease
- Reversing antimalarial resistance in human malaria parasites
- Structural and functional analysis of DNA repair complexes
- Targeting human infective coronaviruses using alpaca antibodies
- Towards targeting altered glial biology in high-grade brain cancers
- Uncovering the real impact of persistent malaria infections
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding how malaria parasites sabotage acquisition of immunity
- Understanding malaria infection dynamics
- Understanding the mechanism of type I cytokine receptor activation
- Unveiling the heterogeneity of small cell lung cancer
- Using alpaca antibodies to understand malaria invasion and transmission
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to cross the blood brain barrier for drug delivery
- Using structural biology to understand programmed cell death
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Brain cancer

Brain cancer causes more deaths in people under the age of 40 than any other cancer, and more deaths in Australian children than any other disease.
Brain cancer survival rates are low and have barely changed in 30 years. Our research into brain cancer is focused on finding new therapies to improve outcomes for the 1600 Australians diagnosed with brain cancer each year.
Brain cancer research at WEHI
Our researchers are:
- Defining the changes in brain cells that allow cancer to grow.
- Working to develop potential new treatments for brain cancer.
- Testing whether drugs that block cell survival could be effective in treating brain cancers.
- Investigating whether the body’s own immune system could be employed to fight brain cancer.
The Brain Cancer Centre
The Brain Cancer Centre was launched publicly on 25 October 2021. The centre was founded by Carrie’s Beanies 4 Brain Cancer and established in partnership with WEHI with support from the Victorian Government.
The Brain Cancer Centre brings together the best and brightest minds with a single focus: to improve outcomes for brain cancer patients NOW and in the future. Our world-class research teams will work collaboratively to develop new treatments and trials so that patients diagnosed with brain cancer are given real hope.
Visit The Brain Cancer Centre website to learn more.
What is brain cancer?
Brain cancer is the abnormal, uncontrolled growth of cells in the brain.
The brain has many different ‘control centres’ that regulate all of our body functions, from breathing to walking. When the cancer grows it can damage these control centres. Even slow growing (benign) tumours can be serious if they affect a vital area of the brain.
The brain is composed of nerve cells that send messages to and from the body, and supporting cells that enable nerve cells to function. Cancer can originate in many different cell types, giving rise to various forms of brain cancer.
Research at WEHI focusses on:
- Glioblastoma multiforme (GBM), the most common and dangerous form of brain cancer. GBM arises from glial cells that support nerve cell function. Less than five per cent of people with GBM survive for five years or longer.
- Diffuse Intrinsic Pontine Glioma (DIPG), also called Paediatric Diffuse Midline Glioma, which is the most aggressive form of brain cancer in children.
- Medulloblastomas, which is the most common brain cancer in children.
- Collecting comprehensive clinical and translational data on all patients diagnosed with brain tumours.
- Investigating new models to improve access to clinical trials for patients with glioma.
- Exploring novel platforms to direct personalised therapy.
Brain cancer rarely spreads (metastasises) to other parts of the body, but cancer cells from other organs can spread to the brain.
Symptoms of brain cancer
The symptoms of brain cancer depend on the type of brain cancer, its size and where it is located in the brain.
Common symptoms of brain cancer include headaches, seizures, nausea and vomiting. Depending on the part of the brain affected, people with brain cancer may also experience changes in speech, vision, hearing, balance, memory, mood, muscle tone or sensation.
Risk factors for developing brain cancer
Most cases of brain cancer arise spontaneously and no cause can be identified. Some factors are known to increase a person’s risk of developing brain cancer, including:
- Ageing
- Exposure to medical radiation, such as radiotherapy, CT scans or x-rays to the head during treatment for a previous cancer
- Having close relatives with brain cancer
How is brain cancer treated?
Treatment for brain cancer is challenging because it affects the body’s most vital organ.
Some brain cancers can be safely removed by surgery, however in other cases this cannot be done without damage to normal brain tissue. For example, DIPG cannot be surgically removed because it originates in the brainstem.
Alongside surgery, standard treatments for brain cancer include radiotherapy and chemotherapy to kill rapidly dividing cells. These therapies have significant side effects and are not always effective at killing brain cancer cells. Side effects are a particular concern for children as their brain is still developing.
WEHI scientists are involved in finding new therapies for brain cancer that will improve quality of life and survival for people with this disease.
Brain cancer immunotherapy
Our researchers are investigating whether immune cells could be harnessed to fight brain cancer, an approach called ‘immunotherapy’.
Immunotherapy has led to significant advances in treating cancers such as melanoma and lung cancer. Our researchers are now investigating whether immunotherapy could be used to treat childhood DIPG and adult GBM.
Support for people with brain cancer
WEHI researchers are not able to provide specific medical advice to individuals. If you have brain cancer or are supporting somebody with this disease, please visit Cure Brain Cancer or the Brain Foundation or consult your medical specialist.
Researchers:
Super Content:
Carrie’s Beanies 4 Brain Cancer and WEHI have partnered to establish The Brain Cancer Centre.
The Brain Cancer Centre will bring together Australia’s brightest medical research minds to end brain cancer as a terminal illness.
Funding from Carrie Bickmore’s Beanies 4 Brain Cancer Foundation is helping to advance immunotherapy treatments
A novel approach to immunotherapy design could pave the way for new treatments for people with an aggressive form of brain cancer called glioblastoma.